Reltecimod

Summary

Reltecimod (CHEMBL3989950) is a phase-3 clinical-stage protein; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 4
• Chemistry: 1037.2 Da · C46H72N10O15S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989950
Name	Reltecimod
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	71652162
Molecular formula	C46H72N10O15S
Molecular weight	1037.2
InChIKey	VRNHFZYMPDKTBS-WYUJEMNCSA-N

SMILES: C[C@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)O)N

IUPAC name: (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2R)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[[(1R)-1-carboxyethyl]amino]-4-oxobutanoic acid

Also known as: AB103, Reltecimod, RELTECIMOD

Parent form; salt/anhydrous children: CHEMBL3989963

Patent coverage: 56 distinct patent families (133 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02469857	PHASE3	COMPLETED	Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
NCT03403751	PHASE3	TERMINATED	Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
NCT01417780	PHASE2	COMPLETED	Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients
NCT01166984	PHASE1	COMPLETED	AB103 Peptide Antagonist in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).